Hospital
ST Vincents Chilton LLC
ST Vincents Chilton LLC was paid $3.82M by Medicaid between Jan 2018 and Dec 2024, across 64 billing codes. Its largest line is 99285, emergency room visit (most serious) — 31% of everything it billed.
33Billing provider infoST VINCENTS CHILTON LLC
CLANTON, AL 35045
CLANTON, AL 35045
33aNPI1093171860assigned 01/11/2016
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$3.82M
24GClaims85,661
24DCodes billed64
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,631 | $408K | |
| 2019 | 15,262 | $524K | |
| 2020 | 8,934 | $346K | |
| 2021 | 12,726 | $434K | |
| 2022 | 13,778 | $679K | |
| 2023 | 14,500 | $866K | |
| 2024incomplete | 9,830 | $561K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 31% | 4,105 | 3,829 | $1.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 9,984 | 9,429 | $738K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 15,775 | 15,028 | $680K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 12% | 3,914 | 3,783 | $448K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.6% | 3,596 | 3,397 | $176K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.7% | 2,676 | 2,605 | $105K |
| 80053 | Comprehensive metabolic panel | 2.2% | 7,271 | 6,734 | $84K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 8,725 | 8,089 | $82K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.1% | 2,351 | 2,270 | $80K |
| 87634 | 1.1% | 717 | 701 | $42K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 584 | 570 | $32K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,120 | 2,005 | $31K |
52 more codes
| 87070 | <1% | 2,278 | $25K | |
| 83690 | <1% | 1,965 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,175 | $13K |
| 81001 | <1% | 3,023 | $13K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 91 | $12K |
| 81025 | <1% | 2,928 | $10K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 37 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 630 | $7K |
| 85610 | <1% | 1,557 | $7K | |
| 84484 | <1% | 466 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 615 | $5K |
| 83735 | <1% | 577 | $4K | |
| 85730 | <1% | 1,479 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 176 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 15 | $2K |
| 87420 | <1% | 116 | $2K | |
| 81003 | <1% | 673 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 30 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 153 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 30 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 921 | $973.80 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 173 | $618.88 |
| 86617 | <1% | 13 | $593.58 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 102 | $332.91 |
| 85018 | <1% | 97 | $315.77 | |
| 85014 | <1% | 97 | $315.77 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 873 | $238.10 |
| 87147 | <1% | 28 | $230.46 | |
| 83655 | <1% | 12 | $201.84 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 188 | $197.52 |
| 74018 | <1% | 14 | $158.76 | |
| 85027 | <1% | 120 | $148.43 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $148.28 |
| 80076 | <1% | 60 | $108.68 | |
| 85652 | <1% | 27 | $107.19 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 59 | $83.70 |
| 82150 | <1% | 41 | $72.63 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 40 | $51.36 |
| J2704 | Injection, propofol, 10 mg | <1% | 162 | $32.87 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 440 | $24.86 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 57 | $10.39 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 630 | $2.61 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 112 | $2.26 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 87 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 203 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 277 | $0.00 |
| A9270 | Non-covered item or service | 0% | 760 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 17 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 148 | $0.00 |
| 88312 | 0% | 16 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUGHES, CHRISTOPHER (CFO)
| Provider | Location | Paid |
|---|---|---|
| ST. Vincent's Birmingham | Birmingham, AL | $1.29M |
| Wagoner Care LLC | Glendale, AZ | $932K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.